Amyotrophic lateral sclerosis: applications of stem cells – an update
Lidia Cova1, Vincenzo Silani21Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy; 2Department of Neurology and Laboratory of Neuroscience, “Dino Ferrari” Center, Università degli Studi di Milano, IRCCS...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2010
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/29713822dba6480e84cf7b14d6b7400d |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:29713822dba6480e84cf7b14d6b7400d |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:29713822dba6480e84cf7b14d6b7400d2021-12-02T04:29:12ZAmyotrophic lateral sclerosis: applications of stem cells – an update1178-6957https://doaj.org/article/29713822dba6480e84cf7b14d6b7400d2010-10-01T00:00:00Zhttp://www.dovepress.com/amyotrophic-lateral-sclerosis-applications-of-stem-cells-ndash-an-upda-a5557https://doaj.org/toc/1178-6957Lidia Cova1, Vincenzo Silani21Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy; 2Department of Neurology and Laboratory of Neuroscience, “Dino Ferrari” Center, Università degli Studi di Milano, IRCCS Istituto Auxologico Italiano, Milano, ItalyAbstract: Neurodegenerative diseases are a growing public health challenge, and amyotrophic lateral sclerosis (ALS) remains a fatal incurable disease. The advent of stem cell therapy has opened new horizons for both researchers and ALS patients, desperately looking for a treatment. ALS must be considered a systemic disease affecting many cell phenotypes besides motor neurons, even outside the central nervous system. Cell replacement therapy needs to address the specific neurobiological issues of ALS to safely and efficiently reach clinical settings. Moreover, the enormous potential of induced pluripotent cells directly derived from patients for modeling and understanding the pathological mechanisms, in correlation with the discoveries of new genes and animal models, provides new opportunities that need to be integrated with previously described transplantation strategies. Finally, a careful evaluation of preclinical data in conjunction with wary patient choice in clinical trials needs to be established in order to generate meaningful results.Keywords: amyotrophic lateral sclerosis, regenerative medicine, stem cell therapy, clinical trials Lidia CovaVincenzo SilaniDove Medical PressarticleCytologyQH573-671ENStem Cells and Cloning: Advances and Applications, Vol 2010, Iss default, Pp 145-156 (2010) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Cytology QH573-671 |
| spellingShingle |
Cytology QH573-671 Lidia Cova Vincenzo Silani Amyotrophic lateral sclerosis: applications of stem cells – an update |
| description |
Lidia Cova1, Vincenzo Silani21Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy; 2Department of Neurology and Laboratory of Neuroscience, “Dino Ferrari” Center, Università degli Studi di Milano, IRCCS Istituto Auxologico Italiano, Milano, ItalyAbstract: Neurodegenerative diseases are a growing public health challenge, and amyotrophic lateral sclerosis (ALS) remains a fatal incurable disease. The advent of stem cell therapy has opened new horizons for both researchers and ALS patients, desperately looking for a treatment. ALS must be considered a systemic disease affecting many cell phenotypes besides motor neurons, even outside the central nervous system. Cell replacement therapy needs to address the specific neurobiological issues of ALS to safely and efficiently reach clinical settings. Moreover, the enormous potential of induced pluripotent cells directly derived from patients for modeling and understanding the pathological mechanisms, in correlation with the discoveries of new genes and animal models, provides new opportunities that need to be integrated with previously described transplantation strategies. Finally, a careful evaluation of preclinical data in conjunction with wary patient choice in clinical trials needs to be established in order to generate meaningful results.Keywords: amyotrophic lateral sclerosis, regenerative medicine, stem cell therapy, clinical trials |
| format |
article |
| author |
Lidia Cova Vincenzo Silani |
| author_facet |
Lidia Cova Vincenzo Silani |
| author_sort |
Lidia Cova |
| title |
Amyotrophic lateral sclerosis: applications of stem cells – an update |
| title_short |
Amyotrophic lateral sclerosis: applications of stem cells – an update |
| title_full |
Amyotrophic lateral sclerosis: applications of stem cells – an update |
| title_fullStr |
Amyotrophic lateral sclerosis: applications of stem cells – an update |
| title_full_unstemmed |
Amyotrophic lateral sclerosis: applications of stem cells – an update |
| title_sort |
amyotrophic lateral sclerosis: applications of stem cells – an update |
| publisher |
Dove Medical Press |
| publishDate |
2010 |
| url |
https://doaj.org/article/29713822dba6480e84cf7b14d6b7400d |
| work_keys_str_mv |
AT lidiacova amyotrophiclateralsclerosisapplicationsofstemcellsampndashanupdate AT vincenzosilani amyotrophiclateralsclerosisapplicationsofstemcellsampndashanupdate |
| _version_ |
1718401173821587456 |